12-Week Study of Plecanatide for CIC (The National CIC3 Study)
CIC
A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation
1 other identifier
interventional
1,410
1 country
167
Brief Summary
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2014
Shorter than P25 for phase_3
167 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 22, 2014
CompletedFirst Posted
Study publicly available on registry
April 24, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2015
CompletedResults Posted
Study results publicly available
March 14, 2019
CompletedMay 28, 2019
May 1, 2019
1.1 years
April 22, 2014
November 28, 2018
May 23, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Durable Overall CSBM Responders, Mean Replacement Approach
The primary efficacy endpoint was measured by the number of durable overall CSBM responders over the 12-week Treatment Period. A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.
12-Week Treatment Period
Secondary Outcomes (4)
Change From Baseline in CSBMs (CSBMs/Week) Over the 12-week Treatment Period , Mean Replacement Approach
Baseline and 12 weeks
Change From Baseline in SBMs (SBMs/Week) Over the 12-week Treatment Period, Mean Replacement Approach
Baseline and 12 weeks
Change From Baseline in Average Weekly SBM Stool Consistency Over the 12-week Treatment Period, Mean Replacement Approach
Baseline and 12 weeks
Change From Baseline in Average Weekly Straining Score Over the 12-week Treatment Period, Mean Replacement Approach
Baseline and 12 weeks
Study Arms (3)
Plecanatide 3.0 mg
EXPERIMENTALPlecanatide tablets 3.0 mg QD for 12 weeks
Placebo
PLACEBO COMPARATORMatching placebo tablets QD for 12 weeks
Plecanatide 6.0 mg
EXPERIMENTALPlecanatide tablets 6.0 mg QD for 12 weeks
Interventions
Eligibility Criteria
You may qualify if:
- Male or female aged 18-80, inclusive
- Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months
- Completed a colonoscopy in accordance with American Gastroenterological Association (AGA) colon cancer screening guidelines (5 years), with no clinically significant findings
- Willing to maintain a stable diet during the study
You may not qualify if:
- Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for \> 25% of Bowel Movements (BMs) during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment
- Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable
- History of cathartic colon, laxative, enema abuse, or ischemic colitis
- Fecal impaction within 3 months of screening
- Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
- Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis
- Major surgery, stroke or myocardial infarction (MI) within 60 days of screening
- Participated in a previous plecanatide clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (167)
Synergy Research Site
Anniston, Alabama, 36207, United States
Synergy Research Site
Huntsville, Alabama, 35801, United States
Synergy Research Site
Chandler, Arizona, 85224, United States
Synergy Research Site
Goodyear, Arizona, 85395, United States
Synergy Research Site
Tucson, Arizona, 85704, United States
Synergy Research Site
Tucson, Arizona, 85710, United States
Synergy Research Site
Tucson, Arizona, 85712, United States
Synergy Research Site
Tucson, Arizona, 85715, United States
Synergy Research Site
Tucson, Arizona, 85745, United States
Synergy Research Site
Anaheim, California, 92801, United States
Synergy Research Site
Artesia, California, 90701, United States
Synergy Research Site
Carmichael, California, 95608, United States
Synergy Research Site
Corona, California, 92879, United States
Synergy Research Site
Encino, California, 91436, United States
Synergy Research Site
Garden Grove, California, 92843, United States
Synergy Research Site
Garden Grove, California, 92844, United States
Synergy Research Site
Glendale, California, 91204, United States
Synergy Research Site
La Mirada, California, 90638, United States
Synergy Research Site
Laguna Hills, California, 92653, United States
Synergy Research Site
Los Angeles, California, 90017, United States
Synergy Research Site
Los Angeles, California, 90036, United States
Synergy Research Site
Newport Beach, California, 92663, United States
Synergy Research Site
Oceanside, California, 92056, United States
Synergy Research Site
Orange, California, 92868, United States
Synergy Research Site
Sacramento, California, 95821, United States
Synergy Research Site
Sacramento, California, 95831, United States
Synergy Research Site
San Bernardino, California, 92408, United States
Synergy Research Site
San Diego, California, 92103, United States
Synergy Research Site
Upland, California, 91786, United States
Synergy Research Site
Ventura, California, 93003, United States
Synergy Research Site
Denver, Colorado, 80209, United States
Synergy Research Site
Littleton, Colorado, 80128, United States
Synergy Research Site
Stamford, Connecticut, 06905, United States
Synergy Research Site
Aventura, Florida, 33180, United States
Synergy Research Site
Boynton Beach, Florida, 33472, United States
Synergy Research Site
Bradenton, Florida, 34208, United States
Synergy Research Site
Brandon, Florida, 33511, United States
Synergy Research Site
Brooksville, Florida, 34601, United States
Synergy Research Site
Clearwater, Florida, 33756, United States
Synergy Research Site
DeLand, Florida, 32720, United States
Synergy Research Site
Fort Lauderdale, Florida, 33312, United States
Synergy Research Site
Gainesville, Florida, 32607, United States
Synergy Research Site
Hialeah, Florida, 33012, United States
Synergy Research Site
Hialeah, Florida, 33013, United States
Synergy Research Site
Hialeah, Florida, 33016, United States
Synergy Research Site
Hialeah, Florida, 33106, United States
Synergy Research Site
Hollywood, Florida, 33024, United States
Synergy Research Site
Homestead, Florida, 33030, United States
Synergy Research Site
Jacksonville, Florida, 32256, United States
Synergy Research Site
Jacksonville, Florida, 32277, United States
Synergy Research Site
Miami, Florida, 33014, United States
Synergy Research Site
Miami, Florida, 33015, United States
Synergy Research Site
Miami, Florida, 33032, United States
Synergy Research Site
Miami, Florida, 33122, United States
Synergy Research Site
Miami, Florida, 33125, United States
Synergy Research Site
Miami, Florida, 33126, United States
Synergy Research Site
Miami, Florida, 33142, United States
Synergy Research Site
Miami, Florida, 33144, United States
Synergy Research Site
Miami, Florida, 33155, United States
Synergy Research Site
Miami, Florida, 33157, United States
Synergy Research Site
Miami, Florida, 33165, United States
Synergy Research Site
Miami, Florida, 33173, United States
Synergy Research Site
Miami, Florida, 33175, United States
Synergy Research Site
Miami, Florida, 33176, United States
Synergy Research Site
Miami, Florida, 33185, United States
Synergy Research Site
Miami Lakes, Florida, 33016, United States
Synergy Research Site
Miami Springs, Florida, 33166, United States
Synergy Research Site
New Port Richey, Florida, 34653, United States
Synergy Research Site
North Miami Beach, Florida, 33162, United States
Synergy Research Site
Orlando, Florida, 32806, United States
Synergy Research Site
Orlando, Florida, 32807, United States
Synergy Research Site
Ormond Beach, Florida, 32174, United States
Synergy Research Site
Pembroke Pines, Florida, 33026, United States
Synergy Research Site
Pembroke Pines, Florida, 33028, United States
Synergy Research Site
Plant City, Florida, 33563, United States
Synergy Research Site
Plantation, Florida, 33324, United States
Synergy Research Site
Saint Cloud, Florida, 34769, United States
Synergy Research Site
Sarasota, Florida, 34242, United States
Synergy Research Site
Seminole, Florida, 33777, United States
Synergy Research Site
St. Petersburg, Florida, 33709, United States
Synergy Research Site
Tamarac, Florida, 33319, United States
Synergy Research Site
Tampa, Florida, 33607, United States
Synergy Research Site
Tampa, Florida, 33614, United States
Synergy Research Site
West Palm Beach, Florida, 33409, United States
Synergy Research Site
Atlanta, Georgia, 30342, United States
Synergy Research Site
Savannah, Georgia, 31406, United States
Synergy Research Site
Snellville, Georgia, 30078, United States
Synergy Research Site
Blackfoot, Idaho, 83221, United States
Synergy Research Site
Boise, Idaho, 83709, United States
Synergy Research Site
Chicago, Illinois, 60602, United States
Synergy Research Site
Oak Lawn, Illinois, 60453, United States
Synergy Research Site
Schaumburg, Illinois, 60194, United States
Synergy Research Site
Evansville, Indiana, 47714, United States
Synergy Research Site
Madisonville, Kentucky, 42431, United States
Synergy Research Site
Owensboro, Kentucky, 42303, United States
Synergy Research Site
Monroe, Louisiana, 71201, United States
Synergy Research Site
Shreveport, Louisiana, 71105, United States
Synergy Research Site
Columbia, Maryland, 21045, United States
Synergy Research Site
Watertown, Massachusetts, 02472, United States
Synergy Research Site
Buckley, Michigan, 49620, United States
Synergy Research Site
St Louis, Missouri, 63141, United States
Synergy Research Site
Omaha, Nebraska, 68114, United States
Synergy Research Site
Las Vegas, Nevada, 89103, United States
Synergy Research Site
Las Vegas, Nevada, 89106, United States
Synergy Research Site
Stateline, Nevada, 89449, United States
Synergy Research Site
Newington, New Hampshire, 03801, United States
Synergy Research Site
Blackwood, New Jersey, 08012, United States
Synergy Research Site
Albuquerque, New Mexico, 87102, United States
Synergy Research Site
Albuquerque, New Mexico, 87109, United States
Synergy Research Site
Elmsford, New York, 10523, United States
Synergy Research Site
New Hyde Park, New York, 11040, United States
Synergy Research Site
New York, New York, 10016, United States
Synergy Research Site
New York, New York, 10018, United States
Synergy Research Site
Cary, North Carolina, 27518, United States
Synergy Research Site
Concord, North Carolina, 28025, United States
Synergy Research Site
Hickory, North Carolina, 28601, United States
Synergy Research Site
Hickory, North Carolina, 28602, United States
Synergy Research Site
High Point, North Carolina, 27262, United States
Synergy Research Site
Raleigh, North Carolina, 27609, United States
Synergy Research Site
Cincinnati, Ohio, 45224, United States
Synergy Research Site
Cleveland, Ohio, 44122, United States
Synergy Research Site
Columbus, Ohio, 43214, United States
Synergy Research Site
Kettering, Ohio, 45429, United States
Synergy Research Site
Middleburg Heights, Ohio, 44130, United States
Synergy Research Site
Sylvania, Ohio, 43560, United States
Synergy Research Site
Wadsworth, Ohio, 44203, United States
Synergy Research Site
Oklahoma City, Oklahoma, 73103, United States
Synergy Research Site
Oklahoma City, Oklahoma, 73104, United States
Synergy Research Site
Jenkintown, Pennsylvania, 19046, United States
Synergy Research Site
Levittown, Pennsylvania, 19056, United States
Synergy Research Site
Pittsburgh, Pennsylvania, 15206, United States
Synergy Research Site
Upper Saint Clair, Pennsylvania, 15241, United States
Synergy Research Site
Greer, South Carolina, 29651, United States
Synergy Research Site
Moncks Corner, South Carolina, 29461, United States
Synergy Research Site
Bristol, Tennessee, 37620, United States
Synergy Research Site
Franklin, Tennessee, 37064, United States
Synergy Research Site
Jefferson City, Tennessee, 37760, United States
Synergy Research Site
Kingsport, Tennessee, 37660, United States
Synergy Research Site
Knoxville, Tennessee, 37919, United States
Synergy Research Site
Knoxville, Tennessee, 37938, United States
Synergy Research Site
Memphis, Tennessee, 38119, United States
Synergy Research Site
Nashville, Tennessee, 37211, United States
Synergy Research Site
Arlington, Texas, 76012, United States
Synergy Research Site
Austin, Texas, 78705, United States
Synergy Research Site
Austin, Texas, 78731, United States
Synergy Research Site
Austin, Texas, 78735, United States
Synergy Research Site
Carrollton, Texas, 75007, United States
Synergy Research Site
Carrollton, Texas, 75010, United States
Synergy Research Site
Channelview, Texas, 77530, United States
Synergy Research Site
Dallas, Texas, 75224, United States
Synergy Research Site
Dallas, Texas, 75231, United States
Synergy Research Site
Gonzales, Texas, 78629, United States
Synergy Research Site
Houston, Texas, 77015, United States
Synergy Research Site
Houston, Texas, 77025, United States
Synergy Research Site
Houston, Texas, 77054, United States
Synergy Research Site
Houston, Texas, 77062, United States
Synergy Research Site
Pharr, Texas, 78577, United States
Synergy Research Site
Plano, Texas, 75024, United States
Synergy Research Site
Plano, Texas, 75075, United States
Synergy Research Site
Plano, Texas, 75093, United States
Synergy Research Site
Plano, Texas, 75903, United States
Synergy Research Site
San Antonio, Texas, 78205, United States
Synergy Research Site
San Antonio, Texas, 78215, United States
Synergy Research Site
Draper, Utah, 84020, United States
Synergy Research Site
Newport News, Virginia, 23606, United States
Synergy Research Site
Sterling, Virginia, 20166, United States
Synergy Research Site
Richland, Washington, 99352, United States
Related Publications (4)
Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation. Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18.
PMID: 37332239DERIVEDMoshiree B, Schoenfeld P, Franklin H, Rezaie A. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials. Clin Ther. 2022 Jan;44(1):98-110.e1. doi: 10.1016/j.clinthera.2021.11.009. Epub 2022 Jan 25.
PMID: 35086735DERIVEDMenees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10.
PMID: 32660770DERIVEDDeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017 Nov;10(11):837-851. doi: 10.1177/1756283X17734697. Epub 2017 Oct 25.
PMID: 29147135DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Patrick H. Griffin
- Organization
- Synergy Pharmaceuticals Inc.
Study Officials
- STUDY DIRECTOR
Mary Beth Layton
Synergy Pharmaceuticals Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 22, 2014
First Posted
April 24, 2014
Study Start
April 1, 2014
Primary Completion
May 1, 2015
Study Completion
July 1, 2015
Last Updated
May 28, 2019
Results First Posted
March 14, 2019
Record last verified: 2019-05